Matches in SemOpenAlex for { <https://semopenalex.org/work/W2413722406> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2413722406 endingPage "9" @default.
- W2413722406 startingPage "250" @default.
- W2413722406 abstract "The ability of pravastatin, a new hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, to lower plasma lipid levels and modify lipoprotein patterns was compared with that of gemfibrozil in 18 patients with familial hypercholesterolemia who participated in a 16-week, double-blind, parallel trial. Pravastatin proved better than gemfibrozil in lowering total and low-density lipoprotein (LDL) cholesterolemia: -23.6% and -28.2% versus -18.1% and -21.4%, respectively. A significant positive correlation was found between the starting level of serum cholesterol (both total and LDL) and the gemfibrozil-induced reduction (r = 0.72 and 0.69), whereas the hypocholesterolemic effect of pravastatin was apparently independent from pretreatment levels (r = 0.32 and 0.10). Apolipoprotein B concentrations were lowered by 25.4% (pravastatin) and 22.0% (gemfibrozil). Pravastatin and gemfibrozil reduced triglyceride levels by 13.9% and 49.4%, respectively. Both drugs increased the level of high density lipoprotein (HDL) cholesterol, but this change was significant only with gemfibrozil (p less than 0.05). The HDL subfraction structure and distribution were not modified by pravastatin treatment. Gemfibrozil, in contrast, increased HDL3 cholesterol level by 9% because of an enrichment of HDL3 particles in both free cholesterol and cholesteryl esters and lowered the flotation rate of HDL3 (p less than 0.05). LDL particles became smaller after gemfibrozil treatment (diameter: 25.4 +/- 0.3 nm vs 26.1 +/- 0.4 nm, p less than 0.01) and were not modified by pravastatin. This comparison shows a more pronounced efficacy of the HMG CoA reductase inhibitor on total and LDL cholesterol levels, also indicating that pravastatin acts by a single major mechanism, reducing the number of circulating LDL particles. Gemfibrozil may exert additional activities, possibly consequent to the stimulation of very low density lipoprotein catabolism." @default.
- W2413722406 created "2016-06-24" @default.
- W2413722406 creator A5000301406 @default.
- W2413722406 creator A5026261464 @default.
- W2413722406 creator A5034135139 @default.
- W2413722406 creator A5064838089 @default.
- W2413722406 creator A5065901407 @default.
- W2413722406 creator A5076538245 @default.
- W2413722406 date "1989-09-01" @default.
- W2413722406 modified "2023-09-23" @default.
- W2413722406 title "Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia." @default.
- W2413722406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2504855" @default.
- W2413722406 hasPublicationYear "1989" @default.
- W2413722406 type Work @default.
- W2413722406 sameAs 2413722406 @default.
- W2413722406 citedByCount "19" @default.
- W2413722406 crossrefType "journal-article" @default.
- W2413722406 hasAuthorship W2413722406A5000301406 @default.
- W2413722406 hasAuthorship W2413722406A5026261464 @default.
- W2413722406 hasAuthorship W2413722406A5034135139 @default.
- W2413722406 hasAuthorship W2413722406A5064838089 @default.
- W2413722406 hasAuthorship W2413722406A5065901407 @default.
- W2413722406 hasAuthorship W2413722406A5076538245 @default.
- W2413722406 hasConcept C104950815 @default.
- W2413722406 hasConcept C126322002 @default.
- W2413722406 hasConcept C134018914 @default.
- W2413722406 hasConcept C134651460 @default.
- W2413722406 hasConcept C181199279 @default.
- W2413722406 hasConcept C185592680 @default.
- W2413722406 hasConcept C2777320049 @default.
- W2413722406 hasConcept C2778163477 @default.
- W2413722406 hasConcept C2778670441 @default.
- W2413722406 hasConcept C2778913445 @default.
- W2413722406 hasConcept C2779519902 @default.
- W2413722406 hasConcept C2780072125 @default.
- W2413722406 hasConcept C55493867 @default.
- W2413722406 hasConcept C62746215 @default.
- W2413722406 hasConcept C71924100 @default.
- W2413722406 hasConceptScore W2413722406C104950815 @default.
- W2413722406 hasConceptScore W2413722406C126322002 @default.
- W2413722406 hasConceptScore W2413722406C134018914 @default.
- W2413722406 hasConceptScore W2413722406C134651460 @default.
- W2413722406 hasConceptScore W2413722406C181199279 @default.
- W2413722406 hasConceptScore W2413722406C185592680 @default.
- W2413722406 hasConceptScore W2413722406C2777320049 @default.
- W2413722406 hasConceptScore W2413722406C2778163477 @default.
- W2413722406 hasConceptScore W2413722406C2778670441 @default.
- W2413722406 hasConceptScore W2413722406C2778913445 @default.
- W2413722406 hasConceptScore W2413722406C2779519902 @default.
- W2413722406 hasConceptScore W2413722406C2780072125 @default.
- W2413722406 hasConceptScore W2413722406C55493867 @default.
- W2413722406 hasConceptScore W2413722406C62746215 @default.
- W2413722406 hasConceptScore W2413722406C71924100 @default.
- W2413722406 hasIssue "3" @default.
- W2413722406 hasLocation W24137224061 @default.
- W2413722406 hasOpenAccess W2413722406 @default.
- W2413722406 hasPrimaryLocation W24137224061 @default.
- W2413722406 hasRelatedWork W1979919506 @default.
- W2413722406 hasRelatedWork W1992152873 @default.
- W2413722406 hasRelatedWork W2004682325 @default.
- W2413722406 hasRelatedWork W2030404799 @default.
- W2413722406 hasRelatedWork W2033921535 @default.
- W2413722406 hasRelatedWork W2035440468 @default.
- W2413722406 hasRelatedWork W2043813485 @default.
- W2413722406 hasRelatedWork W2060962757 @default.
- W2413722406 hasRelatedWork W2091911513 @default.
- W2413722406 hasRelatedWork W2123594115 @default.
- W2413722406 hasVolume "114" @default.
- W2413722406 isParatext "false" @default.
- W2413722406 isRetracted "false" @default.
- W2413722406 magId "2413722406" @default.
- W2413722406 workType "article" @default.